ClinicalTrials.gg
CompletedNCT05514873Updated Sep 3, 2025Results posted

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

A Phase 3 interventional study of zilucoplan (RA101495) in Generalized Myasthenia Gravis, sponsored by UCB Biopharma SRL. Completed at 12 sites in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-09-03.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..

Enrollment
14th of 18
26 · median 45
Started
2022
the only one that year
Phase 3
12 of 18
3 open now
Registered
8th of 18
by date

Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 14th largest by enrollment, is the only one that started in 2022, is one of 12 in phase 3, and was the 8th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Myasthenia Gravis by UCB S.A., or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

Keywords

  • gMG
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has been treated with an intravenous (IV) complement component 5 (C5) inhibitor approved for the treatment of generalized myasthenia gravis (gMG) at the recommended dose regimen for at least 3 months (for eculizumab) or 4 months (for ravulizumab) prior to Screening with a clinically stable disease as per the Investigator's judgment.
  • Participant is willing to switch from his/her current IV C5 inhibitor to subcutaneous (SC) zilucoplan (ZLP)
  • Participant has a documented diagnosis of gMG (Myasthenia Gravis Foundation of America; MGFA Class II-IVa) at Screening based on participant history and supported by previous evaluations
  • Participant has a well-documented record of positive serology for acetylcholine receptor binding autoantibodies prior to Screening
  • Participant has no more than a 2-point change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Baseline compared with the Screening Visit
  • Participant has had no change in dose during the Screening Period and no change in corticosteroid dose is anticipated to occur during the 12-week Main Treatment Period
  • Participant has had no change in therapy, including dose, during the Screening Period and no change in immunosuppressive therapy is anticipated to occur during the 12-week Main Treatment Period
  • Participant has a record of vaccination with at least 1 dose of a quadrivalent meningococcal vaccine and meningococcal serotype B vaccine at least 14 days prior to the first dose of ZLP if not vaccinated within 3 years prior to the start of study medication
  • Male and/or female
  • A male participant is recommended to agree to use during the study and for at least 40 days (5 half lives) after the last dose of study medication, and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant; not breastfeeding, and at least one of the following conditions applies:
  • Not a woman of (WOCBP) OR
  • A WOCBP who agrees to follow the contraceptive guidance during the study and for at least 40 days (5 half lives) after the last dose of study medication.
  • Participant is capable of giving signed

Exclusion criteria

Exclusion Criteria:

  • Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study
  • Participant has a known to any components of the study medication as stated in this protocol
  • Participant has had a thymectomy within 6 months prior to Baseline or has one scheduled to occur during the 12-week Main Treatment Period
  • Participant has a history of meningococcal disease
  • Participant has or has had a current or recent systemic infection within 2 weeks prior to Baseline or an infection requiring IV antibiotics within 4 weeks prior to Baseline
  • Participant has active (except curatively resected squamous or basal cell carcinoma of the skin) requiring surgery, chemotherapy, or radiation within the prior 12 months (participants with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to Screening with no detectable recurrence are allowed).
  • Participant has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has had suicidal ideation with at least some intent to act in the past 6 months as indicated by a positive response ("Yes") to either question 4 or question 5 of the "Screening/Baseline" version of the C-SSRS at Screening.
  • Participant has (ALT), aspartate aminotransferase (AST), or alkaline phosphatase (ALP) >2.5x (ULN)
  • Participant has >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Participant has current unstable liver or biliary disease per Investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • >450msec for male participants, QTc >470msec for female participants, or QTc >480 msec in participants with bundle branch block
  • Participant has had recent surgery requiring general anesthesia within 2 weeks prior to Screening or is expected to have surgery requiring general anesthesia during the 12-week Main Treatment Period
  • Participant has received a treatment with an experimental drug within 30 days or 5 half lives of the experimental drug (whichever is longer) prior to Baseline
  • Participant has received treatment with rituximab within 6 months prior to Baseline or treatment is planned to occur during the study
  • Participant has received treatment with intravenous immunoglobulin G (IVIG), SC immunoglobulin, or plasma exchange PLEX 4 weeks prior to Baseline or participant is on chronic IVIG, SC immunoglobulin, or PLEX
  • Participant has previously participated in this study or participant has previously been assigned to treatment in a study of the medication under investigation in this study
  • Participant has participated in another study of an study medication (and/or an investigational device) within the previous 30 days or is currently participating in another study of an investigational study medication (and/or an investigational device)
  • Participant has known positive serology for muscle-specific kinase
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    0.3 mg/kg zilucoplan (RA101495)

    Study participants will be treated with subcutaneous zilucoplan (0.3mg/kg/day)

    Drug: zilucoplan (RA101495)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) and up to and including 40 days after the final dose (or last contact depending on which occurs first).

    Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)

  2. Percentage of Participants With TEAEs Leading to Withdrawal of Study Medication Over the Main Treatment Period

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as an AE starting on or after the time of first administration of IMP and up to and including 40 days after the final dose (or last contact depending on which occurs first).

    Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)

Secondary outcomes

  1. Change From Baseline to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score

    The MG-ADL is a brief 8-item interviewer-administered patient-reported outcome (PRO) designed to evaluate MG symptom severity. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. Each item is assessed on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents severely decreased ability to perform that function. The total MG-ADL score ranges from 0 to 24, with a higher score indicating more severe impairment. A positive change in score indicates worsening and negative change indicates improvement.

    Time frame: From Baseline to Week 12

  2. Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Score

    The QMG is a standardized and validated quantitative strength scoring system that included 13 items in the following categories: ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. Scoring for each item ranges from no weakness (0) to severe weakness (3), with an overall score range from 0 to 39. Higher scores represent more severe impairment. A positive change in score indicates worsening and negative change indicates improvement.

    Time frame: From Baseline to Week 12

  3. Percentage of Participants With Serious TEAEs Over the Main Treatment Period

    Treatment-emergent serious adverse events (serious TEAEs) were any untoward medical incidence in a participant during administered study treatment, whether or not these events were related to study treatment and additionally were emergent untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Required in patient hospitalisation or prolongation of existing hospitalisation * Results in persistent disability/incapacity * Was a congenital anomaly or birth defect * Important medical events

    Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)

  4. Percentage of Participants With Study Withdrawal Over the Main Treatment Period

    Percentage of participants with study withdrawal based to pre-defined reasons in the protocol were reported.

    Time frame: From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)

07

Results

Posted Mar 30, 2025

Participant flow

The study started to enroll participants in October 2022 and concluded in October 2024.

Main Treatment Period
Participant flow — Main Treatment Period
MilestoneZilucoplan 0.3 mg/kg
Started26
Completed23
Not completed3
Withdrew: Subject's lack of compliance with study procedures1
Withdrew: Adverse event2
Extension Treatment Period
Participant flow — Extension Treatment Period
MilestoneZilucoplan 0.3 mg/kg
Started23
Completed20
Not completed3
Withdrew: Lost to follow-up3

Outcome measures

PrimaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as an AE starting on or after the time of first administration of investigational medicinal product (IMP) and up to and including 40 days after the final dose (or last contact depending on which occurs first).

Time frame:
From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period
percentage of participantsZilucoplan 0.3 mg/kg
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period73.1
PrimaryPercentage of Participants With TEAEs Leading to Withdrawal of Study Medication Over the Main Treatment Period

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A TEAE was defined as an AE starting on or after the time of first administration of IMP and up to and including 40 days after the final dose (or last contact depending on which occurs first).

Time frame:
From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With TEAEs Leading to Withdrawal of Study Medication Over the Main Treatment Period
percentage of participantsZilucoplan 0.3 mg/kg
Percentage of Participants With TEAEs Leading to Withdrawal of Study Medication Over the Main Treatment Period7.7
SecondaryChange From Baseline to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score

The MG-ADL is a brief 8-item interviewer-administered patient-reported outcome (PRO) designed to evaluate MG symptom severity. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. Each item is assessed on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents severely decreased ability to perform that function. The total MG-ADL score ranges from 0 to 24, with a higher score indicating more severe impairment. A positive change in score indicates worsening and negative change indicates improvement.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score
score on a scaleZilucoplan 0.3 mg/kg
Change From Baseline to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score-1.15 (-2.11 to -0.19)
Statistical analysis
  • Zilucoplan 0.3 mg/kg · Mixed Model for Repeated Measures (MMRM) · p = <0.001
SecondaryChange From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Score

The QMG is a standardized and validated quantitative strength scoring system that included 13 items in the following categories: ocular and facial involvement, swallowing, speech, limb strength, and forced vital capacity. Scoring for each item ranges from no weakness (0) to severe weakness (3), with an overall score range from 0 to 39. Higher scores represent more severe impairment. A positive change in score indicates worsening and negative change indicates improvement.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Score
score on a scaleZilucoplan 0.3 mg/kg
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Score-1.24 (-2.64 to 0.16)
SecondaryPercentage of Participants With Serious TEAEs Over the Main Treatment Period

Treatment-emergent serious adverse events (serious TEAEs) were any untoward medical incidence in a participant during administered study treatment, whether or not these events were related to study treatment and additionally were emergent untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Required in patient hospitalisation or prolongation of existing hospitalisation * Results in persistent disability/incapacity * Was a congenital anomaly or birth defect * Important medical events

Time frame:
From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious TEAEs Over the Main Treatment Period
percentage of participantsZilucoplan 0.3 mg/kg
Percentage of Participants With Serious TEAEs Over the Main Treatment Period3.8
SecondaryPercentage of Participants With Study Withdrawal Over the Main Treatment Period

Percentage of participants with study withdrawal based to pre-defined reasons in the protocol were reported.

Time frame:
From Baseline (Day 1) to Safety Follow-Up Visit (40 days post last dose) of Main Treatment Period (up to approximately 19 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Study Withdrawal Over the Main Treatment Period
percentage of participantsZilucoplan 0.3 mg/kg
Percentage of Participants With Study Withdrawal Over the Main Treatment Period11.5

Adverse events

Collected over From Baseline up to 84 weeks (Overall Treatment Period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zilucoplan 0.3 mg/kg (Overall Treatment Period)0/26 (0%)5/26 (19.2%)24/26 (92.3%)
Most frequent serious events
Most frequent serious events
EventZilucoplan 0.3 mg/kg (Overall Treatment Period)
Myasthenia gravisNervous system disorders2/26
DiverticulitisInfections and infestations1/26
COVID-19Infections and infestations1/26
PyelonephritisInfections and infestations1/26
Metapneumovirus infectionInfections and infestations1/26
HyperglycaemiaMetabolism and nutrition disorders1/26
Lactic acidosisMetabolism and nutrition disorders1/26
DyspnoeaRespiratory, thoracic and mediastinal disorders1/26
HypoxiaRespiratory, thoracic and mediastinal disorders1/26
Most frequent other events
Showing 10 of 17
Most frequent other events
EventZilucoplan 0.3 mg/kg (Overall Treatment Period)
Amylase increasedInvestigations4/26
Lipase increasedInvestigations4/26
COVID-19Infections and infestations4/26
DiarrhoeaGastrointestinal disorders3/26
NauseaGastrointestinal disorders3/26
Myasthenia gravisNervous system disorders3/26
PainGeneral disorders2/26
Injection site painGeneral disorders2/26
SinusitisInfections and infestations2/26
Injection site bruisingGeneral disorders2/26

Baseline characteristics

Baseline characteristics refers to the Modified Intention to Treat Population (mITT) which included all eligible study participants who received at least 1 post-baseline dose of study medication and had at least 1 post-Baseline assessment.

Age, Continuous
Age, Continuous(years)Zilucoplan 0.3 mg/kg
Mean59.9 ± 15.9
Age, Customized
Age, Customized(Participants)Zilucoplan 0.3 mg/kg
18 - <65 years12
65 - <85 years14
>=85 years0
Sex: Female, Male
Sex: Female, Male(Participants)Zilucoplan 0.3 mg/kg
Female13
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zilucoplan 0.3 mg/kg
Asian1
Black or African American4
White19
Other or Mixed2
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zilucoplan 0.3 mg/kg
Hispanic or Latino4
Not Hispanic or Latino22
08

Study locations

12 sites
  • Mg0017 50564
    Scottsdale, Arizona 85251, United States
  • Mg0017 50559
    Los Angeles, California 90095, United States
  • Mg0017 50593
    Rancho Mirage, California 92270, United States
  • Mg0017 50099
    San Francisco, California 94143, United States
  • Mg0017 50557
    O'Fallon, Illinois 62269, United States
  • Mg0017 50556
    Chapel Hill, North Carolina 27599, United States
  • Mg0017 50086
    Charlotte, North Carolina 28207, United States
  • Mg0017 50076
    Columbus, Ohio 43221, United States
  • Mg0017 50555
    Austin, Texas 78759, United States
  • Mg0017 50304
    Dallas, Texas 75390-8866, United States
  • Mg0017 50111
    Seattle, Washington 98195-0001, United States
  • Mg0017 50569
    Greenfield, Wisconsin 53228, United States
09

References and documents

Publications

  • Freimer M, Desai U, Govindarajan R, Kang MK, Khan S, Khatri B, Levine T, Macwan S, Shieh PB, Weiss MD, Bloemers J, Boroojerdi B, Delicha EM, Lavrov A, Singh P, Howard JF Jr. Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study. Ther Adv Neurol Disord. 2025 Jul 5;18:17562864251347283. doi: 10.1177/17562864251347283. eCollection 2025. PubMed 40620733 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Mar 2024, 16 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 16 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 25, 2022
StartActual
Oct 31, 2022
Primary completionActual
Mar 13, 2024
CompletionActual
Oct 23, 2024
Results first posted
Mar 30, 2025
Last update
Sep 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05514873
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Oct 31, 2022
Primary completion
Mar 13, 2024
Completion
Oct 23, 2024
Results posted
Mar 30, 2025
Last update
Sep 3, 2025

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion